|
AU2009299793B2
(en)
*
|
2008-10-01 |
2016-03-10 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
SG10201912964PA
(en)
*
|
2011-09-19 |
2020-02-27 |
Axon Neuroscience Se |
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
JP6226752B2
(ja)
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
JP6324974B2
(ja)
*
|
2012-10-12 |
2018-05-23 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
|
|
CA2902026C
(en)
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2925677A1
(en)
*
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
AU2014368696A1
(en)
*
|
2013-12-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Humanized anti-Tau(pS422) antibodies and methods of use
|
|
DK3099713T3
(da)
*
|
2014-02-02 |
2020-04-14 |
Medimmune Ltd |
Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne
|
|
AU2015326911C1
(en)
|
2014-09-30 |
2025-12-18 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (DPRs) antibody
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
UA126272C2
(uk)
|
2015-06-05 |
2022-09-14 |
Дженентек, Інк. |
Антитіло проти тау-білка та спосіб його застосування
|
|
TWI769982B
(zh)
*
|
2015-06-24 |
2022-07-11 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之抗人類運鐵蛋白受體抗體
|
|
CN113929779B
(zh)
|
2015-06-24 |
2025-02-25 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
|
CA2990565A1
(en)
|
2015-06-24 |
2016-12-29 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein containing bdnf and anti-human transferrin receptor antibody
|
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
MA41670A1
(fr)
|
2015-07-06 |
2018-05-31 |
Ucb Biopharma Sprl |
Anticorps se liant a tau
|
|
WO2017027691A1
(en)
*
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
EP3440225A4
(en)
*
|
2016-04-06 |
2020-03-11 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
DK3452507T3
(da)
|
2016-05-02 |
2022-11-14 |
Prothena Biosciences Ltd |
Tau-immunoterapi
|
|
SG11201808434WA
(en)
|
2016-05-02 |
2018-10-30 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
CU24538B1
(es)
|
2016-05-02 |
2021-08-06 |
Prothena Biosciences Ltd |
Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
|
|
TW201831513A
(zh)
|
2016-06-20 |
2018-09-01 |
Ｆ星貝塔有限公司 |
結合物件(一)
|
|
EP3487524A4
(en)
*
|
2016-07-20 |
2020-03-25 |
Anahit Ghochikyan |
HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
|
|
WO2018018031A1
(en)
*
|
2016-07-22 |
2018-01-25 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
MX2019006334A
(es)
|
2016-12-07 |
2019-08-01 |
Genentech Inc |
Anticuerpos antitau y métodos de uso.
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
WO2018119474A2
(en)
*
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death 1 (pd-1)
|
|
CN109983031B
(zh)
*
|
2016-12-26 |
2022-11-25 |
Jcr制药股份有限公司 |
通过血脑屏障的新的抗人转铁蛋白受体抗体
|
|
KR102573622B1
(ko)
|
2016-12-26 |
2023-08-31 |
제이씨알 파마 가부시키가이샤 |
Bdnf를 포함하는 융합 단백질
|
|
KR102014066B1
(ko)
*
|
2017-01-06 |
2019-10-21 |
에이비엘바이오 주식회사 |
항 α-syn 항체 및 그 용도
|
|
IL309890A
(en)
*
|
2017-01-30 |
2024-03-01 |
Alexion Pharma Inc |
Monovalent anti-properdin antibodies and antibody fragments
|
|
US11434279B2
(en)
*
|
2017-02-10 |
2022-09-06 |
The Trustees Of The University Of Pennsylvania |
Anti-factor D antibodies and uses thereof
|
|
JP7364221B2
(ja)
*
|
2017-03-06 |
2023-10-18 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
抗ｃ５抗体およびその使用
|
|
EP3600421A4
(en)
*
|
2017-03-23 |
2021-01-06 |
The Trustees of The University of Pennsylvania |
ANTI-C5A ANTIBODIES AND USES OF THEM
|
|
WO2018178076A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
US11242403B2
(en)
*
|
2017-04-26 |
2022-02-08 |
Mitsubishi Tanabe Pharma Corporation |
Syndecan-1 (CD138) binding agents and uses thereof
|
|
BR112019022906A2
(pt)
|
2017-05-02 |
2020-05-26 |
Prothena Biosciences Limited |
Anticorpos que reconhecem tau
|
|
JP7761373B2
(ja)
*
|
2017-05-30 |
2025-10-28 |
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア |
Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
JP7368856B2
(ja)
|
2017-07-25 |
2023-10-25 |
トゥルーバインディング，インコーポレイテッド |
Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
|
|
US11098108B2
(en)
*
|
2017-08-02 |
2021-08-24 |
Stressmarq Biosciences Inc. |
Antibody binding active alpha-synuclein
|
|
CN111201244A
(zh)
*
|
2017-10-12 |
2020-05-26 |
学校法人庆应义塾 |
特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
|
|
CN112040970A
(zh)
*
|
2017-11-29 |
2020-12-04 |
得克萨斯大学体系董事会 |
用于癌症疗法的组合物和方法
|
|
WO2019110643A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Mabion Sa |
Combination therapy of multiple sclerosis comprising a cd20 ligand
|
|
BR112020011875A2
(pt)
|
2017-12-14 |
2020-11-24 |
Abl Bio Inc. |
anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
|
|
EP3724232B1
(en)
|
2017-12-14 |
2024-12-04 |
The University of Ottawa |
Exosome packaging and targeted autophagy
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
WO2019126398A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Wnt surrogate molecules and uses thereof
|
|
AU2018393076B2
(en)
*
|
2017-12-19 |
2025-11-20 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
|
US11440957B2
(en)
*
|
2017-12-29 |
2022-09-13 |
Alector Llc |
Anti-TMEM106B antibodies and methods of use thereof
|
|
SG11202006348VA
(en)
*
|
2018-01-05 |
2020-07-29 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
|
EP3746478A4
(en)
*
|
2018-01-29 |
2022-01-19 |
The Regents of The University of California |
THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS
|
|
JP7268038B2
(ja)
|
2018-01-31 |
2023-05-02 |
アレクトル エルエルシー |
抗ｍｓ４ａ４ａ抗体及びその使用方法
|
|
JP2021513328A
(ja)
|
2018-01-31 |
2021-05-27 |
アレクター リミテッド ライアビリティ カンパニー |
抗ｍｓ４ａ６ａ抗体及びその使用方法
|
|
US12180285B2
(en)
*
|
2018-02-01 |
2024-12-31 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
US12398201B2
(en)
*
|
2018-02-19 |
2025-08-26 |
New York University |
Tau single domain antibodies
|
|
US12492254B2
(en)
|
2018-02-23 |
2025-12-09 |
H. Lee Moffitt Cancer Center and Research Intitute. Inc. |
CD83-binding chimeric antigen receptors
|
|
WO2019177888A1
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
|
|
US20210363254A1
(en)
*
|
2018-03-20 |
2021-11-25 |
Novartis Ag |
Pharmaceutical combinations
|
|
US11993655B2
(en)
|
2018-04-09 |
2024-05-28 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
WO2019200160A1
(en)
*
|
2018-04-11 |
2019-10-17 |
Tychan Pte. Ltd. |
Methods and compositions for treating yellow fever
|
|
CN112004558A
(zh)
*
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
KR20200118913A
(ko)
*
|
2018-04-24 |
2020-10-16 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
SG11202010324TA
(en)
*
|
2018-04-25 |
2020-11-27 |
Medimmune Ltd |
Formulations of human anti-pd-l1 antibodies
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
CA3097872A1
(en)
|
2018-04-27 |
2019-10-31 |
Biogen Ma Inc. |
Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
|
|
US11613571B2
(en)
*
|
2018-05-23 |
2023-03-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2019229296A1
(en)
*
|
2018-05-29 |
2019-12-05 |
Teknologian Tutkimuskeskus Vtt Oy |
Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
|
|
US20210206864A1
(en)
*
|
2018-05-31 |
2021-07-08 |
Ichnos Sciences SA |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
AU2019287742A1
(en)
*
|
2018-06-14 |
2021-01-28 |
Antagen Institute For Biomedical Research |
Compositions and methods for preventing or reversing T-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis
|
|
EP3817768A4
(en)
*
|
2018-07-02 |
2022-07-06 |
Abcentra, LLC |
Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
US12344672B2
(en)
|
2018-07-12 |
2025-07-01 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
MX2021000399A
(es)
*
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
WO2020024931A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Shen Weiqun |
Anti-il-17a antibodies and use thereof
|
|
WO2020033646A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
JP7177543B2
(ja)
*
|
2018-08-21 |
2022-11-24 |
エービーエル バイオ インコーポレイテッド |
抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用
|
|
EP3846850A4
(en)
|
2018-09-06 |
2022-06-15 |
The Trustees of the University of Pennsylvania |
HUMANIZED ANTI-C5 ANTIBODIES AND USES THEREOF
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
MX2021006379A
(es)
*
|
2018-11-30 |
2021-10-13 |
Abl Bio Inc |
Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos.
|
|
JP6892180B2
(ja)
*
|
2018-12-03 |
2021-06-23 |
株式会社ｍＡｂＰｒｏｔｅｉｎ |
活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
|
|
EP3893901A4
(en)
*
|
2018-12-11 |
2023-01-04 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
CN120058944A
(zh)
|
2019-01-30 |
2025-05-30 |
真和制药有限公司 |
抗gal3抗体及其用途
|
|
KR20210118945A
(ko)
*
|
2019-02-15 |
2021-10-01 |
유니버시티 오브 써던 캘리포니아 |
Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
KR20210128443A
(ko)
*
|
2019-02-15 |
2021-10-26 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6 항체 및 이의 용도
|
|
CA3131531A1
(en)
|
2019-03-03 |
2020-09-10 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3947445A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
WO2020219506A1
(en)
*
|
2019-04-24 |
2020-10-29 |
Janssen Biotech, Inc. |
Antibody formulation
|
|
BR112021021923A2
(pt)
*
|
2019-05-08 |
2022-02-22 |
Novartis Ag |
Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite
|
|
WO2020228806A1
(zh)
*
|
2019-05-16 |
2020-11-19 |
齐鲁制药有限公司 |
针对密蛋白18a2的抗体及其应用
|
|
TW202110878A
(zh)
*
|
2019-05-16 |
2021-03-16 |
法商賽諾菲公司 |
在神經系統中表現抗原結合蛋白
|
|
TW202100560A
(zh)
*
|
2019-06-04 |
2021-01-01 |
大陸商上海吉倍生物技術有限公司 |
一種抗ceacam5 的單殖株抗體及其製備方法和用途
|
|
CA3143221A1
(en)
*
|
2019-06-13 |
2020-12-17 |
Prestige Biopharma Pte. Ltd. |
Novel cthrci-specific antibody and use thereof
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
MY205369A
(en)
*
|
2019-07-26 |
2024-10-17 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
BR112022001733A2
(pt)
*
|
2019-07-31 |
2022-06-28 |
Alector Llc |
Anticorpos anti-ms4a4a e métodos de uso dos mesmos
|
|
CA3224385A1
(en)
*
|
2019-08-16 |
2021-02-25 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptors for treating myeloid malignancies
|
|
EP4041757A4
(en)
*
|
2019-09-26 |
2024-04-17 |
Regents of the University of Minnesota |
VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
|
|
WO2021057930A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
|
|
WO2021058718A1
(en)
*
|
2019-09-26 |
2021-04-01 |
Roche Diagnostics Gmbh |
Anti-csf-1r antibody
|
|
JP2022550390A
(ja)
*
|
2019-09-30 |
2022-12-01 |
スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
|
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
EP4055044A1
(en)
*
|
2019-11-04 |
2022-09-14 |
MedImmune Limited |
Anti il-33 therapeutic agent for treating renal disorders
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
EP4061849A4
(en)
*
|
2019-11-21 |
2024-05-29 |
Brown University |
BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
|
|
AU2020405230A1
(en)
*
|
2019-12-20 |
2022-06-23 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
|
CA3166552A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Truebinding, Inc. |
Anti-gal3 antibodies and methods of use
|
|
AU2021210669A1
(en)
|
2020-01-24 |
2022-08-18 |
Pfizer Inc. |
Anti-E-selectin antibodies, compositions and methods of use
|
|
WO2021151079A1
(en)
|
2020-01-24 |
2021-07-29 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
PE20221781A1
(es)
*
|
2020-02-07 |
2022-11-16 |
Agency Science Tech & Res |
Moleculas de union a antigeno contra alppl2 y/o alpp y usos de las mismas
|
|
JP7772702B2
(ja)
*
|
2020-02-10 |
2025-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｔｍｐｒｓｓ２抗体および抗原結合断片
|
|
JP2023514972A
(ja)
*
|
2020-02-12 |
2023-04-12 |
ザ スクリプス リサーチ インスティテュート |
長時間作用型ｇｍ－ｃｓｆおよび使用方法
|
|
KR102626782B1
(ko)
*
|
2020-02-14 |
2024-01-19 |
주식회사 셀젠텍 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
AU2021265088A1
(en)
*
|
2020-04-28 |
2022-11-03 |
Sola Biosciences Llc |
Compositions and methods for the treatment of TDP-43 proteinopathies
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
KR20230015954A
(ko)
*
|
2020-05-26 |
2023-01-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
|
|
JP2023528797A
(ja)
|
2020-05-26 |
2023-07-06 |
トゥルーバインディング，インコーポレイテッド |
ガレクチン－３を遮断することにより炎症性疾患を処置する方法
|
|
JP2023528375A
(ja)
|
2020-05-29 |
2023-07-04 |
２３アンドミー・インコーポレイテッド |
抗ｃｄ２００ｒ１抗体及びその使用方法
|
|
CN116234575A
(zh)
*
|
2020-06-04 |
2023-06-06 |
赛尔疫苗私人有限公司 |
激动剂抗cd40抗体
|
|
US20230341408A1
(en)
*
|
2020-06-08 |
2023-10-26 |
University Of Florida Research Foundation, Inc. |
Materials and methods for the diagnosis and treatment of cancer
|
|
CA3182384A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Jay M. Short |
Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CA3189531A1
(en)
*
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric antigen receptors and uses thereof
|
|
WO2022012683A1
(en)
*
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Cd19 binding molecules and uses thereof
|
|
JP7812364B2
(ja)
|
2020-07-17 |
2026-02-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
|
|
TW202212354A
(zh)
*
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
JP2023537553A
(ja)
*
|
2020-08-14 |
2023-09-04 |
中外製薬株式会社 |
ワンアームド抗原結合分子およびその使用
|
|
KR20230047492A
(ko)
*
|
2020-08-18 |
2023-04-07 |
오메로스 코포레이션 |
보체 인자 d의 검출을 위한 단클론성 항체, 조성물 및 방법
|
|
CN116323946A
(zh)
*
|
2020-09-03 |
2023-06-23 |
和铂医药(上海)有限责任公司 |
靶向ror1的抗体或其抗原结合片段及制备方法和应用
|
|
WO2022056197A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
IL301330A
(en)
*
|
2020-09-18 |
2023-05-01 |
Ichnos Sciences S A |
CD47-CD38 bispecific antibodies
|
|
CN116348495A
(zh)
*
|
2020-09-18 |
2023-06-27 |
瑞泽恩制药公司 |
结合cd38和/或cd28的抗原结合分子及其用途
|
|
CN115210262B
(zh)
*
|
2020-09-29 |
2023-07-14 |
昆明赛诺制药股份有限公司 |
人源化抗-cd22重组免疫毒素及其应用
|
|
US11795228B2
(en)
*
|
2020-09-30 |
2023-10-24 |
Dren Bio, Inc. |
Anti-CD94 antibodies and methods of use thereof
|
|
WO2022093923A1
(en)
*
|
2020-10-30 |
2022-05-05 |
Rush University Medical Center |
Intranasal immunotherapy for the treatment of alzheimer's disease
|
|
CN114456268B
(zh)
*
|
2020-11-09 |
2023-08-18 |
江苏中新医药有限公司 |
抗胞外-5’-核苷酸酶的抗体序列
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
EP4263609A1
(en)
*
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
|
CA3202629A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
AU2021399147A1
(en)
*
|
2020-12-18 |
2023-07-27 |
Ac Immune Sa |
Antibody delivery
|
|
TW202241964A
(zh)
*
|
2021-01-08 |
2022-11-01 |
美商必治妥美雅史谷比公司 |
因子xia抑制劑之抗體及抗原結合肽及其用途
|
|
JP7699210B2
(ja)
*
|
2021-01-08 |
2025-06-26 |
北京韓美薬品有限公司 |
Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント
|
|
EP4301409A1
(en)
*
|
2021-03-04 |
2024-01-10 |
Boehringer Ingelheim International GmbH |
Methods for the treatment of gpp
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
*
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
CR20230488A
(es)
*
|
2021-03-18 |
2023-12-12 |
Medimmune Ltd |
Moléculas de unión terapéuticas
|
|
BR112023019484A2
(pt)
*
|
2021-03-24 |
2023-12-05 |
Janssen Biotech Inc |
Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
|
|
PE20241732A1
(es)
*
|
2021-03-31 |
2024-08-19 |
Merus Nv |
Dominios de union a pd-1 novedosos
|
|
US20220363761A1
(en)
*
|
2021-03-31 |
2022-11-17 |
Merus N.V. |
Multispecific binding moieties comprising novel pd-1 binding domains
|
|
AU2022255709A1
(en)
*
|
2021-04-06 |
2023-09-28 |
Teneobio, Inc. |
Anti-cd19 antibodies and car-t structures
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
US12201857B2
(en)
*
|
2021-06-22 |
2025-01-21 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN117616123B
(zh)
*
|
2021-06-25 |
2024-11-08 |
中外制药株式会社 |
抗ctla-4抗体
|
|
CN117545779B
(zh)
*
|
2021-06-25 |
2025-04-04 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
CA3225575A1
(en)
*
|
2021-07-14 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
KR20250114330A
(ko)
|
2022-11-30 |
2025-07-29 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
|
|
AU2024209632A1
(en)
*
|
2023-01-20 |
2025-05-08 |
Mabwell Therapeutics, Inc. |
ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF
|
|
EP4680632A2
(en)
|
2023-03-17 |
2026-01-21 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|